XML 105 R52.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until GAZYVA First Non-CLL FDA Approval | 40.0 | %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (i) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million. Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.
Pretax profit sharing formula | Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,542.4 |  |  | $ | 1,431.9 |  |  | $ | 1,316.4 |
Other revenues from anti-CD20 therapeutic programs | 748.0 |  |  | 548.3 |  |  | 242.8 |
Total revenues from anti-CD20 therapeutic programs | $ | 2,290.4 |  |  | $ | 1,980.2 |  |  | $ | 1,559.2 |
Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,542.4 |  |  | $ | 1,431.9 |  |  | $ | 1,316.4 |
Other revenues from anti-CD20 therapeutic programs | 748.0 |  |  | 548.3 |  |  | 242.8 |
Total revenues from anti-CD20 therapeutic programs | $ | 2,290.4 |  |  | $ | 1,980.2 |  |  | $ | 1,559.2 |
Summary of activity related to BAN2401 and Elenbecestat collaboration | A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat | $ | 348.7 |  |  | $ | 232.0 |  |  | $ | 146.2 |
Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income | $ | 174.3 |  |  | $ | 116.0 |  |  | $ | 74.3 |
Total sales and marketing expense incurred by the collaboration | $ | 32.4 |  |  | $ | 10.7 |  |  | $ | — |
Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income | $ | 16.2 |  |  | $ | 5.4 |  |  | $ | — |
Summary of activity related to Aducanumab collaboration | A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Total aducanumab development expense | $ | 179.4 |  |  | $ | 264.8 |  |  | $ | 268.7 |
Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income | $ | 98.7 |  |  | $ | 234.6 |  |  | $ | 268.7 |
Total aducanumab sales and marketing expense incurred by the collaboration | $ | 27.4 |  |  | $ | 50.6 |  |  | $ | 23.6 |
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income | $ | 15.1 |  |  | $ | 27.3 |  |  | $ | 23.6 |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block] + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration